Safety and Efficacy Study of Q301 in Moderate to Severe Atopic Dermatitis Patients

Status:	Completed
Conditions:	Dermatology, Dermatology, Dermatology
Therapuetic Areas:	Dermatology / Plastic Surgery
Healthy:	No
Age Range:	18 - Any
Updated:	5/21/2016
Start Date:	April 2015
End Date:	May 2016

This is a randomized, double-blind, vehicle-controlled, parallel-group comparison study to
evaluate the safety and efficacy of Q301 Cream vs. vehicle in adult subjects with moderate
to severe AD. Study drug (Q301 Cream or vehicle) will be administered topically twice a day
for 8 consecutive weeks.

Inclusion Criteria:

1. Male or female subjects aged 18 or older

2. Subjects with a clinical diagnosis of AD according to the Hanifin and Rajka Criteria
by a board certified/eligible dermatologist

3. Subjects with IGA score 3 or 4 corresponding to moderate to severe AD at screening
and baseline visits

Exclusion Criteria:

1. Subjects who had topical treatment with corticosteroids within 1 week before
randomization

2. Subjects who had systemic treatment with corticosteroids or cyclosporine or other
immunosuppressive treatment within 4 weeks before randomization

3. Subjects who had ultraviolet irradiation (including photopheresis) within 4 weeks
before screening

4. Subjects who participated in another drug trial within 4 weeks before screening

We found this trial at

sites

Clinical Trial Facility in Berlin New Jersey

Berlin, New Jersey 08009

from

Berlin, NJ